SAN DIEGO--(BUSINESS WIRE)--Capstan Therapeutics, Inc. (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using CellSeeker™, a targeted lipid nanoparticle (tLNP) technology platform, today announced it will present preclinical data on CPTX2309, Capstan’s lead in vivo CAR-T candidate, at the American College of Rheumatology (ACR) Convergence 2024, taking place between November 14-19, 2024 in Washington, D.C..

圣地亚哥--（商业新闻短讯）--Capstan Therapeutics，Inc.（“Capstan”）是一家生物技术公司，致力于使用靶向脂质纳米颗粒（tLNP）技术平台CellSeeker™通过RNA递送推进细胞的体内重编程，今天宣布将于2024年11月14日至19日在华盛顿特区举行的2024年美国风湿病学会（ACR）Convergence 2024上展示Capstan领先的体内CAR-T候选人CPTX2309的临床前数据。。

CPTX2309, a product of Capstan’s CellSeeker™ platform, delivers an mRNA payload encoding an anti-CD19 CAR to preferentially reprogram CD8-expressing T cells. The therapeutic goal of this approach is to achieve a reset of the immune system through rapid and deep B cell depletion in both blood and lymphoid tissues, without the challenges of conventional ex vivo CAR-T..

CPTX2309是Capstan的CellSeeker™平台的产品，可提供编码抗CD19 CAR的mRNA有效载荷，以优先重编程表达CD8的T细胞。这种方法的治疗目标是通过在血液和淋巴组织中快速和深度的B细胞消耗来实现免疫系统的重置，而没有常规离体CAR-T的挑战。。

“Capstan’s non-viral in vivo CAR-T approach is designed to bring together the unprecedented potency of CAR-T therapy with the convenience, pharmacological tunability, and scalability of a conventional biologic,” said Adrian Bot, M.D., Ph.D., Chief Scientific Officer and Executive Vice President of R&D at Capstan.

“Capstan的非病毒体内CAR-T方法旨在将CAR-T疗法前所未有的潜力与传统生物制剂的便利性，药理学可调性和可扩展性结合在一起，”Capstan首席科学官兼研发执行副总裁Adrian Bot博士说。

“Data presented at the conference will support the development of CPTX2309 for a potentially broad range of B cell-mediated autoimmune diseases, with the therapeutic goal of resetting a patient’s immune system in order to achieve a durable, drug-free clinical response.”.

“会议上提供的数据将支持CPTX2309的开发，用于潜在的广泛B细胞介导的自身免疫性疾病，其治疗目标是重置患者的免疫系统，以实现持久的无药物临床反应。”。

Presentation Details:

演示详细信息：

Abstract ID: 0835

摘要编号：0835

Title: Effective Engineering of CD8+ T Cells from Autoimmune Disease Patients Utilizing a CD8-Targeted Lipid Nanoparticle Encoding an Anti-CD19 CAR mRNA (CPTX2309)

标题：利用编码抗CD19 CAR mRNA（CPTX2309）的CD8靶向脂质纳米颗粒对自身免疫性疾病患者的CD8+T细胞进行有效工程

Presentation type: Oral presentation

演讲类型：口头演讲

Presenting author: Haig Aghajanian, Ph.D., Co-Founder, Head and Vice President of Research, Capstan Therapeutics

报告作者：Haig Aghajanian博士，绞盘治疗学联合创始人、研究负责人兼副总裁

Session: Abstracts: T Cell Biology & Targets in Autoimmune & Inflammatory Disease

会议：摘要：T细胞生物学与自身免疫性和炎症性疾病的靶标

Date and time: Saturday, November 16: 3:00 PM - 3:15 PM ET

日期和时间：11月16日星期六下午3:00

Abstract ID: 0088

摘要编号：0088

Title: Profound B Cell Depletion and Repopulation with Predominantly Naïve B Cells in Non-Human Primates Achieved Through a Novel In Vivo CD8-Targeted Lipid Nanoparticle mRNA CAR

标题：通过新型体内靶向CD8的脂质纳米颗粒mRNA CAR，在非人灵长类动物中实现了以幼稚B细胞为主的B细胞的深度消耗和再增殖

Presentation type: Poster

展示类型：海报

Presenting author: Aric Frantz, Ph.D., Senior Director of Pharmacology and Toxicology, Capstan Therapeutics

报告作者：Aric Frantz博士，绞盘疗法药理学和毒理学高级主任

Session: SLE – Animal Models Poster

课程：SLE–动物模型海报

Date and time: Saturday, November 16: 10:30 AM - 12:30 PM ET

日期和时间：美国东部时间11月16日星期六上午10:30至下午12:30

Abstract ID: 0019

摘要编号：0019

Title: A Novel Product Candidate (CPTX2309) for In Vivo mRNA Engineering of Anti-CD19 CAR T Cells Utilizing Novel CD8-Targeted Lipid Nanoparticles

标题：利用新型CD8靶向脂质纳米粒进行抗CD19 CAR T细胞体内mRNA工程的新型候选产品（CPTX2309）

Presentation type: Poster

展示类型：海报

Presentation author: Theresa Hunter, Ph.D., Principal Scientist, Capstan Therapeutics

演讲作者：Theresa Hunter博士，绞盘疗法首席科学家

Session: B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

会议：B细胞生物学与自身免疫和炎症性疾病海报中的目标

Date and time: Saturday, November 16: 10:30 AM - 12:30 PM ET

日期和时间：美国东部时间11月16日星期六上午10:30至下午12:30

A copy of the posters and presentation will be added to the “Publications and News” section of Capstan’s website at www.capstantx.com/.

海报和演示文稿的副本将添加到Capstan网站的“出版物和新闻”部分，网址为www.capstantx.com/。

About Capstan Therapeutics, Inc. (www.capstantx.com)

关于Capstan Therapeutics，Inc.（www.capstantx.com）

Capstan is a biotechnology company with a mission to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA technologies. Our proprietary CellSeeker™ tLNP platform technology is composed of novel LNPs conjugated with a recombinant protein binder, such as a monoclonal antibody.

Capstan是一家生物技术公司，其使命是通过开发靶向体内RNA技术来增加患者的治疗可能性。我们专有的CellSeeker™tLNP平台技术由与重组蛋白粘合剂（例如单克隆抗体）偶联的新型LNP组成。

tLNPs are designed to deliver payloads, including mRNA or gene editing tools, capable of reprogramming specific cell types in vivo. Capstan’s CellSeeker™ technology has the potential to generate transformative therapies with possible applications across a broad range of disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders.

tLNPs旨在提供有效载荷，包括mRNA或基因编辑工具，能够在体内重新编程特定的细胞类型。Capstan的CellSeeker™技术有可能产生转化疗法，并可能应用于广泛的疾病领域，包括自身免疫性疾病，肿瘤学，纤维化和单基因血液疾病。

For more information, please visit www.capstantx.com and follow us on LinkedIn and X (Twitter)..

有关更多信息，请访问www.capstantx.com，并在LinkedIn和X（Twitter）上关注我们。。